Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sex-linked Disorders01:43

Sex-linked Disorders

101.8K
Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
101.8K
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

146
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
146
Lethal Alleles02:41

Lethal Alleles

15.4K
Agouti: A Lethal Allele
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
15.4K
X-linked Traits01:19

X-linked Traits

54.4K
In most mammalian species, females have two X sex chromosomes and males have an X and Y. As a result, mutations on the X chromosome in females may be masked by the presence of a normal allele on the second X. In contrast, a mutation on the X chromosome in males more often causes observable biological defects, as there is no normal X to compensate. Trait variations arising from mutations on the X chromosome are called “X-linked”.
54.4K
Pedigree Analysis01:35

Pedigree Analysis

84.1K
Overview
84.1K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Model-based somapacitan dosing and IGF-I response in children born SGA or with ISS, Noonan or Turner syndromes.

Journal of the Endocrine Society·2026
Same author

Continuous subcutaneous recombinant PTH(1-34) infusion improves serum calcium and phosphate homeostasis in children with autosomal dominant hypocalcemia type 1 refractory to standard-of-care treatment.

European journal of endocrinology·2026
Same author

Excluding children: What "no-kids zones" reveal about our collective future.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2026
Same author

Safety, tolerability, pharmacokinetics, and efficacy of burosumab in infants with X-linked hypophosphataemia: an open-label, multicentre, non-randomised study.

The lancet. Diabetes & endocrinology·2026
Same author

Risk of bone overstimulation in long-term PTH(1-34) therapy for hypoparathyroidism.

European journal of endocrinology·2026
Same author

Characterisation of Urine-Derived Cells for the Molecular Diagnosis of Rare Disorders.

International journal of molecular sciences·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: Jun 15, 2025

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model
08:42

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model

Published on: July 3, 2020

4.4K

X-linked hypophosphataemia.

Peter Kamenický1, Karine Briot2, Craig F Munns3

  • 1Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Le Kremlin-Bicêtre, France; Centre de Référence des Maladies du Métabolisme du Calcium et du Phosphate, Service d'Endocrinologie et des Maladies de la Reproduction, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France.

Lancet (London, England)
|August 24, 2024
PubMed
Summary
This summary is machine-generated.

X-linked hypophosphataemia, a genetic disorder from PHEX gene defects, causes low phosphate levels due to excess FGF23. Targeting FGF23 improves outcomes, but lifelong care and new treatments like gene repair are needed.

More Related Videos

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K
Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome
06:48

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome

Published on: March 23, 2022

2.3K

Related Experiment Videos

Last Updated: Jun 15, 2025

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model
08:42

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model

Published on: July 3, 2020

4.4K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K
Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome
06:48

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome

Published on: March 23, 2022

2.3K

Area of Science:

  • Genetics and Molecular Biology
  • Endocrinology
  • Metabolic Bone Disease

Background:

  • X-linked hypophosphataemia (XLH) is a genetic disorder caused by mutations in the phosphate regulating endopeptidase homolog X-linked (PHEX) gene.
  • PHEX deficiency leads to elevated fibroblast growth factor 23 (FGF23) levels, a phosphaturic hormone.
  • Elevated FGF23 causes renal phosphate wasting and impaired calcitriol synthesis, resulting in hypophosphataemia and defective bone mineralization.

Purpose of the Study:

  • To review the current understanding of X-linked hypophosphataemia.
  • To discuss the pathophysiology involving PHEX gene defects and FGF23.
  • To highlight recent therapeutic advancements and future directions in managing XLH.

Main Methods:

  • Literature review of genetic, molecular, and clinical studies on X-linked hypophosphataemia.
  • Analysis of the role of PHEX gene mutations and FGF23 in disease pathogenesis.
  • Evaluation of current and emerging treatment strategies targeting FGF23 and PHEX.

Main Results:

  • PHEX gene defects are the primary cause of XLH, leading to increased FGF23 production.
  • Elevated FGF23 disrupts phosphate homeostasis and bone mineralization, causing characteristic disease manifestations.
  • Targeting FGF23 has shown significant improvements in patient outcomes.

Conclusions:

  • X-linked hypophosphataemia is a complex genetic disorder with significant morbidity.
  • Therapeutic strategies targeting FGF23 have advanced disease management.
  • Innovative approaches, including PHEX gene repair, are crucial for further reducing the disease burden and improving lifelong care.